OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 80. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
The importance of persistence in cancer drug development	2060
A new path to targeted protein degradation?	1231
A specific biomarker for insoluble tau	1036
Targeting tumour-associated bacteria	809
The improving benefit–risk balance of phase I cancer trials	699
Neutralizing Zika virus	633
Vaccine exposes tumours to immune cell attack	579
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	528
Promoting tissue repair after heart attack	520
mRNA-encoded monoclonal antibody fights CHIKV	513
AI serves up target and inhibitor for lung fibrosis	461
FDA approves first all-oral sleeping sickness drug	453
Hypoimmune iPSCs escape immune detection	449
Glucose-sensitive insulin protects against hypoglycaemia	422
Tumour cells get a dendritic cell makeover	410
Targeting drug-resistant glioblastoma	405
Degrading cell-free DNA to prevent recurrent stroke	387
FDA new drug approvals in Q1 2023	383
Apolipoprotein L2 inhibitor mitigates fibrosis	380
Lipid nanoparticle ferries therapeutic mRNA to the placenta	375
Chemical engineering of CRISPR–Cas systems for therapeutic application	358
FDA approves a c-MET-targeted ADC for lung cancer	318
Anti-tau antibody stumbles in phase II Alzheimer trial	305
Evolution of innovative drug R&D in China	284
FDA approves second TTR stabilizer for cardiac amyloidosis	279

BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	278
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	265
New antibiotic for urinary tract infections nabs FDA approval	262
Targeting the Hippo pathway in cancer	260
Top companies and drugs by sales in 2021	249
Small-molecule discovery through DNA-encoded libraries	239
2022 FDA approvals	236
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	233
Increasing the potency of T cell therapies	228
mRNA vaccines for infectious diseases — advances, challenges and opportunities	228
Pushing both sides of the drug pricing aisle	215
Reflections on 10 years of the FDA’s breakthrough therapy designation	207
Blocking breast cancer metastasis	197
Rewired proteostasis in KRAS inhibitor resistance	196
Small molecule improves muscle function in myasthenia gravis	193
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	180
R&D re-balancing act	176
Host-directed antiviral blocks SARS-CoV-2 entry	175
The significance of blockbusters in the pharmaceutical industry	163
Amylin takes another shot at the obesity prize	158
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	156
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation	154
TCR-engineered T cells get personal	154
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	152
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	151
Inhibiting ASGR1 boosts cholesterol removal	146
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	144
Base editors hit the clinic	143
The antibody–drug conjugate landscape	140
Screening ultra-large virtual libraries	140
FDA approves second BCMA-targeted CAR-T cell therapy	130
A call to action for translational sciences in COVID-19 and future pandemics	127
FDA new drug approvals in Q2 2023	124
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	123
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	119
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	117
Combating antimicrobial resistance in malaria, HIV and tuberculosis	113
Phenotypic drug discovery: recent successes, lessons learned and new directions	113
Antibody–drug conjugates come of age in oncology	113
The emerging role of mass spectrometry-based proteomics in drug discovery	103
Pan-coronavirus vaccine pipeline takes form	101
Gut metabolite mediates nerve repair	100
Reducing IL-2 toxicity	98
Agonist antibody lowers blood pressure	92
A novel single-agent antibiotic	91
Immunology on the brain	90
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	89
Multi-TACs target solid tumours	88
The malignant melanoma market	88
What does AlphaFold mean for drug discovery?	87

The European Innovation Network as a hub for medicines innovation in Europe	86
Monkeypox mRNA vaccine protects mice and macaques	86
Neglected tropical diseases go global	86
Anti-IL-11 antibody shows anti-ageing properties	82
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	81